Answers are grounded in this paper and cite their sources.
Background Accurate molecular grouping of medulloblastoma is essential for integrated diagnosis and risk stratification but genome-wide DNA methylation profiling remains inaccessible in many resource-constrained settings. Immunohistochemistry (IHC) offers a practical surrogate, but the diagnostic boundaries of conventional panels and the added value of extended marker combinations remain incompletely defined. Methods We retrospectively evaluated 62 medulloblastoma cases from a tertiary neuropathology center. A routine 3-marker IHC panel (β-catenin, GAB1, YAP1) and an extended 7-marker panel (β-catenin, GAB1, YAP1, LEF1, OTX2, Filamin A, p75-NGFR) were compared against DNA methylation profiling as the reference standard in 51 methylation-confirmed cases. MYC/MYCN status was assessed by IHC, FISH and methylation-derived copy-number analysis. Survival analysis was performed using the Kaplan–Meier method. Results Methylation profiling confirmed medulloblastoma in 51/52 cases; one case was reclassified as diffuse paediatric-type high-grade glioma, MYCN subtype. Among 51 methylation-confirmed cases, non-WNT/non-SHH tumors predominated (29/51; 56.9%), followed by SHH-activated (14/51; 27.5%) and WNT-activated (8/51; 15.7%). The routine three-marker panel (β-catenin/GAB1/YAP1) achieved 88.2% concordance (45/51), misclassifying 4 WNT-activated and 2 SHH-activated tumors. The extended seven-marker panel achieved 100% concordance (51/51) in this cohort, correctly assigning all molecular groups. LEF1 outperformed β-catenin for WNT detection (sensitivity 100% vs 50%). A minimal LEF1/GAB1 backbone achieved 98.0% concordance (50/51). MYC amplification was identified in 1/51 cases and MYCN amplification in 2/51 cases; FISH showed complete concordance with methylation-derived copy-number analysis. Conclusion An extended, stringently interpreted IHC panel provides accurate molecular grouping of medulloblastoma and represents a practical, resource-adapted diagnostic strategy where methylation profiling is not routinely feasible.
No takes yet. Share an insight, caveat, or question.
Varghese et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: